Nama's AI scorecard currently rates Nutex Health Buy (8.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is NUTX's P/E ratio?

Nutex Health trades at a trailing price-to-earnings ratio of 8.0.

When does NUTX report earnings?

Nutex Health's next scheduled report is on Mar 11, 2027. Analysts expect EPS of $5.95.

What is the NUTX price target?

The median analyst price target from 6 analysts is $308.00, with a range of $200.00 – $336.00.

Is NUTX Shariah compliant?

Nama's AAOIFI-style screen reads Nutex Health as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Nutex Health (NUTX)

Healthcare · Medical Care Facilities · NASDAQ

Nutex Health (NUTX) is a Healthcare company in the Medical Care Facilities industry. It has a market capitalization of $1.24B, a trailing price-to-earnings ratio of 8.0 and a free-cash-flow yield of 20.1%. Over the most recent reported fiscal year, revenue grew 82.4% and free cash flow per share grew 837.0%. Nama's AI scorecard rates it Buy, 8.2 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Buy · 8.2/10

Clearly positive, short of the top band. As of Nov 7, 2026.

Momentum

Rising · +75.0% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-97.7%

How far the last close sits under the highest price of the past five years.

Market cap	$1.24B
Trailing P/E	8.0
Price / book	3.1
Price / sales	1.5
FCF yield	20.1%
Dividend yield	—
Gross margin	51.3%
Operating margin	43.0%
Net margin	21.2%
Revenue growth (YoY)	+82.4%
Revenue growth (3-yr annual)	+58.6%
EPS growth (YoY)	—
FCF/share growth (YoY)	+837.0%
Beta	2.0
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Care Facilities

NUTX earnings

Next report: Mar 11, 2027 (Q4 2026, EPS estimate $5.95). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$5.71	$5.54	+3.1%	—
Q2 2026	Aug 6, 2026	$9.38	$4.95	+89.5%	$210.75M
Q1 2026	Apr 30, 2026	$5.74	$5.56	+3.2%	$216.49M
Q4 2025	Mar 5, 2026	$1.62	$5.56	-70.9%	$151.68M

NUTX analyst price target

Median target $308.00 from 6 analysts, ranging $200.00 – $336.00.

Medical Care Facilities peers

Ticker	Company	Market cap	P/E
HCA	HCA Healthcare	$103.40B	16.5
THC	Tenet Healthcare	$22.55B	12.7
EHC	Encompass Health	$13.50B	22.4
FMS	Fresenius Medical Care	$12.15B	10.2
DVA	DaVita	$12.04B	13.6
UHS	Universal Health Services	$11.52B	8.6
ENSG	Ensign Group	$10.56B	23.8
PACS	PACS Group	$7.87B	20.1

Explore live NUTX data on Nama Insights →

NUTX FAQ

Is NUTX a buy?: Nama's AI scorecard currently rates Nutex Health Buy (8.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is NUTX's P/E ratio?: Nutex Health trades at a trailing price-to-earnings ratio of 8.0.
When does NUTX report earnings?: Nutex Health's next scheduled report is on Mar 11, 2027. Analysts expect EPS of $5.95.
What is the NUTX price target?: The median analyst price target from 6 analysts is $308.00, with a range of $200.00 – $336.00.
Is NUTX Shariah compliant?: Nama's AAOIFI-style screen reads Nutex Health as Not Shariah Compliant. At least one of the three ratios or the industry test failed.